Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05125-4 ◽

2019 ◽

Vol 174 (3) ◽

pp. 719-729 ◽

Cited By ~ 56

Author(s):

H. S. Rugo ◽

R. S. Finn ◽

V. Diéras ◽

J. Ettl ◽

O. Lipatov ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor Receptor ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor−positive (ER+)/human epidermal growth factor receptor 2−negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P+L)

Annals of Oncology ◽

10.1093/annonc/mdx365.054 ◽

2017 ◽

Vol 28 ◽

pp. v96 ◽

Cited By ~ 3

Author(s):

V. Diéras ◽

N. Harbeck ◽

A.A. Joy ◽

K.A. Gelmon ◽

J. Ettl ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Growth Factor Receptor ◽

First Line ◽

Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.

10.1158/0008-5472.sabcs-09-5069 ◽

2009 ◽

Cited By ~ 6

Author(s):

R. Finn ◽

S. Hurvitz ◽

M. Allison ◽

S. Applebaum ◽

J. Glaspy ◽

...

Keyword(s):

Breast Cancer ◽

Phase I Study ◽

Growth Factor Receptor ◽

Cyclin D ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Post Menopausal ◽

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

Annals of Oncology ◽

10.1093/annonc/mdx424 ◽

2017 ◽

Vol 28 ◽

pp. vi25

Author(s):

A. D' Alonzo ◽

C. Bighin ◽

F. Puglisi ◽

L. Gerratana ◽

M. De Laurentis ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

10.1158/1538-7445.am2017-ct045 ◽

2017 ◽

Cited By ~ 5

Author(s):

Fabrice Andre ◽

Salomon M. Stemmer ◽

Mario Campone ◽

Katarina Petrakova ◽

Shani Paluch-Shimon ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Epidermal Growth ◽

Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study

Oncotarget ◽

10.18632/oncotarget.14735 ◽

2017 ◽

Vol 8 (27) ◽

pp. 44800-44810

Author(s):

Claudia Bighin ◽

Beatrice Dozin ◽

Francesca Poggio ◽

Marcello Ceppi ◽

Paolo Bruzzi ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

Breast Cancer Patients ◽

First Line ◽

Reverse Sequence ◽

Epidermal Growth ◽

Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer

Current Opinion in Oncology ◽

10.1097/01.cco.0000397417.75245.9c ◽

2011 ◽

Vol 23 ◽

pp. S3-S9 ◽

Cited By ~ 8

Author(s):

Margarida Damasceno

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Breast Cancer ◽

Growth Factor Receptor ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽

116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC)

Annals of Oncology ◽

10.1093/annonc/mdw577 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Cited By ~ 3

Author(s):

S-A. Im ◽

H. Mukai ◽

I.H. Park ◽

N. Masuda ◽

C. Shimizu ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Asian Women ◽

First Line ◽

Impact of prior treatment on palbociclib plus letrozole (P+L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2–) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdx365.011 ◽

2017 ◽

Vol 28 ◽

pp. v79-v80

Author(s):

R.S. Finn ◽

K.A. Gelmon ◽

J. Ettl ◽

J. Asselah ◽

A. Castrellon ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Efficacy And Safety ◽

First Line ◽

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e13053 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e13053-e13053 ◽

Cited By ~ 1

Author(s):

Alessia D'Alonzo ◽

Claudia Bighin ◽

Fabio Puglisi ◽

Michelino DeLaurentiis ◽

Andrea Fontana ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Epidermal Growth ◽